MedTrace Logo

Real World Study of Four PD-1 Agents in China

NCT03966456 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-05-29

No results posted yet for this study

Summary

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Conditions

  • Thoracic Cancer
  • Gynecologic Cancer
  • Abdomen Tumors
  • Malignant Melanoma

Interventions

DRUG

Chemotherapy

compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.

Sponsors & Collaborators

  • The Affiliated Hospital of Qingdao University

    lead OTHER

Principal Investigators

  • Xiaochun Zhang, Dr · The Affiliated Hospital of Qingdao University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-06-01
Completion
2023-06-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03966456 on ClinicalTrials.gov